Invivyd (IVVD) vs Palisade Bio (PALI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Palisade Bio (PALI) has outperformed Invivyd (IVVD) over the past year, losing 27.5% versus a loss of 55.3%. Over five years, IVVD leads with a -97.8% price change compared with -99.9% for PALI. Palisade Bio is the larger company by market cap ($252.7 million vs $206.4 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IVVD | PALI |
|---|---|---|
| Share price | $0.7004 | $1.45 |
| Market cap | $206.45M | $252.69M |
| 1-day change | -3.87% | -2.03% |
| YTD return | -70.50% | -38.30% |
| 1-year return | -55.30% | -27.50% |
| 5-year return | -97.75% | -99.93% |
| P/E ratio (TTM) | — | 2.42 |
| EPS (TTM) | $-0.33 | $0.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.07 | $2.86 |
| 52-week low | $0.528 | $1.32 |
| Distance from 52-week high | -77.19% | -49.30% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1327.76% | +604.83% |
| Average volume | 4.78M | 2.56M |
| Shares outstanding | 294.76M | 174.27M |
| Employees | 122 | 14 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PALI has outperformed IVVD by 27.8 percentage points over the past year.
- The two companies sit in different sectors: Invivyd in Healthcare and Palisade Bio in Health Care.
About Invivyd
IVVD stock →Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand.
Healthcare · Biotechnology · 122 employees
About Palisade Bio
PALI stock →Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees
IVVD vs PALI FAQ
Which is bigger, Invivyd or Palisade Bio?
Palisade Bio (PALI) is larger, with a market capitalization of $252.69M compared with $206.45M for Invivyd (IVVD).
Which stock has performed better over the past year, IVVD or PALI?
PALI returned -27.50% over the past 12 months, compared with -55.30% for IVVD (price return, excluding dividends). Past performance does not predict future results.
Are Invivyd and Palisade Bio in the same industry?
No. Invivyd is in the Healthcare sector, while Palisade Bio is in Health Care.